{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:17:01Z","timestamp":1783379821209,"version":"3.54.6"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018987","name":"Ministerul Cercet\u0103rii, Inov\u0103rii \u015fi Digitaliz\u0103rii","doi-asserted-by":"publisher","award":["PN-III-P4-ID-PCE-2020-1247"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1247"]}],"id":[{"id":"10.13039\/100018987","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chemotherapy-induced neuropathic pain (CINP), a condition with unmet treatment needs, affects over half of cancer patients treated with chemotherapeutics. Researchers have recently focused on the endocannabinoid system because of its critical role in regulating our bodies' most important functions, including pain. We used in vitro and in vivo methods to determine the toxicity profile of a synthetic cannabinoid, JWH-182, and whether it could be potentially effective for CINP alleviation. In vitro, we evaluated JWH-182 general toxicity, measuring fibroblast viability treated with various concentrations of compound, and its neuroprotection on dorsal root ganglion neurons treated with paclitaxel. In vivo, we performed an evaluation of acute and 28-day repeated dose toxicity in mice, with monitoring of health status and a complete histopathological examination. Finally, we evaluated the efficacy of JWH-182 on a CINP model in mice using specific pain assessment tests. JWH-182 has an acceptable toxicity profile, in both, in vitro and in vivo studies and it was able to significantly reduce pain perception in a CINP model in mice. However, the translation of these results to the clinic needs further investigation.<\/jats:p>","DOI":"10.1038\/s41598-024-67154-y","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T02:01:55Z","timestamp":1721008915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["JWH-182: a safe and effective synthetic cannabinoid for chemotherapy-induced neuropathic pain in preclinical models"],"prefix":"10.1038","volume":"14","author":[{"given":"Leontina-Elena","family":"Filipiuc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Creang\u0103-Murariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan-Ionel","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela-Carmen","family":"Ababei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0103zvan-Nicolae","family":"Rusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela-Dumitri\u021ba","family":"Stanciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"\u0218tefanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitic\u0103","family":"Ciorpac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Szilagyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Gogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silviu-Iulian","family":"Filipiuc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivona-Maria","family":"Tudorancea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Solcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Alexa-Stratulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela-Carmen","family":"Cump\u0103t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina-Clementina","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"67154_CR1","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1007\/s00520-021-06042-x","volume":"29","author":"C Maih\u00f6fner","year":"2021","unstructured":"Maih\u00f6fner, C., Diel, I., Tesch, H., Quandel, T. & Baron, R. Chemotherapy-induced peripheral neuropathy (CIPN): Current therapies and topical treatment option with high-concentration capsaicin. Support. Care Cancer 29, 4223\u20134238 (2021).","journal-title":"Support. Care Cancer"},{"key":"67154_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess, J. et al. Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol. Ther. 9, 385\u2013450 (2021).","journal-title":"Oncol. Ther."},{"key":"67154_CR3","doi-asserted-by":"publisher","unstructured":"Alqahtani, F. Y., Aleanizy, F. S., El Tahir, E., Alkahtani, H. M. & AlQuadeib, B. T. Paclitaxel. in 205\u2013238 (2019). https:\/\/doi.org\/10.1016\/bs.podrm.2018.11.001","DOI":"10.1016\/bs.podrm.2018.11.001"},{"key":"67154_CR4","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2147\/JPR.S296150","volume":"14","author":"Y-X Zhao","year":"2021","unstructured":"Zhao, Y.-X., Yu, X.-C., Gao, J.-H., Yao, M.-J. & Zhu, B. Acupuncture for Paclitaxel-induced peripheral neuropathy: A review of clinical and basic studies. J. Pain Res. 14, 993\u20131005 (2021).","journal-title":"J. Pain Res."},{"key":"67154_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112671","volume":"147","author":"AD Desforges","year":"2022","unstructured":"Desforges, A. D. et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed. Pharmacother. 147, 112671 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"67154_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","volume":"20","author":"R Zaj\u0105czkowska","year":"2019","unstructured":"Zaj\u0105czkowska, R. et al. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 20, 1451 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"67154_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.113121","volume":"324","author":"NP Staff","year":"2020","unstructured":"Staff, N. P. et al. Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems. Exp. Neurol. 324, 113121 (2020).","journal-title":"Exp. Neurol."},{"key":"67154_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2217\/pmt-2018-0020","volume":"8","author":"JA Boyette-Davis","year":"2018","unstructured":"Boyette-Davis, J. A., Hou, S., Abdi, S. & Dougherty, P. M. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 8, 363\u2013375 (2018).","journal-title":"Pain Manag."},{"key":"67154_CR9","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.3390\/ijms23063344","volume":"23","author":"C Pagano","year":"2022","unstructured":"Pagano, C. et al. Cannabinoids: Therapeutic use in clinical practice. Int. J. Mol. Sci. 23, 3344 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67154_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/biomedicines9030267","volume":"9","author":"H Gurm","year":"2021","unstructured":"Gurm, H., Hirota, J. A. & Raha, S. Cannabinoid signalling in immune-reproductive crosstalk during human pregnancy. Biomedicines 9, 267 (2021).","journal-title":"Biomedicines"},{"key":"67154_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41583-021-00465-5","volume":"22","author":"A Bara","year":"2021","unstructured":"Bara, A., Ferland, J.-M.N., Rompala, G., Szutorisz, H. & Hurd, Y. L. Cannabis and synaptic reprogramming of the developing brain. Nat. Rev. Neurosci. 22, 423\u2013438 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"67154_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174560","volume":"911","author":"A Kicman","year":"2021","unstructured":"Kicman, A., P\u0119dzi\u0144ska-Betiuk, A. & Koz\u0142owska, H. The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases. Eur. J. Pharmacol. 911, 174560 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"67154_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0165-6147(00)01482-6","volume":"21","author":"D Piomelli","year":"2000","unstructured":"Piomelli, D., Giuffrida, A., Calignano, A. & Rodr\u0131\u0301guez de Fonseca, F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21, 218\u2013224 (2000).","journal-title":"Trends Pharmacol. Sci."},{"key":"67154_CR14","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","volume":"19","author":"R Mechoulam","year":"1963","unstructured":"Mechoulam, R. & Shvo, Y. Hashish\u2014I. Tetrahedron 19, 2073\u20132078 (1963).","journal-title":"Tetrahedron"},{"key":"67154_CR15","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1021\/acsomega.7b00996","volume":"2","author":"MM Lewis","year":"2017","unstructured":"Lewis, M. M., Yang, Y., Wasilewski, E., Clarke, H. A. & Kotra, L. P. Chemical profiling of medical cannabis extracts. ACS Omega 2, 6091\u20136103 (2017).","journal-title":"ACS Omega"},{"key":"67154_CR16","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/ph14100965","volume":"14","author":"VN Bukke","year":"2021","unstructured":"Bukke, V. N., Archana, M., Villani, R., Serviddio, G. & Cassano, T. Pharmacological and toxicological effects of phytocannabinoids and recreational synthetic cannabinoids: Increasing risk of public health. Pharmaceuticals 14, 965 (2021).","journal-title":"Pharmaceuticals"},{"key":"67154_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/ejn.14982","volume":"55","author":"TM Brunt","year":"2022","unstructured":"Brunt, T. M. & Bossong, M. G. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. Eur. J. Neurosci. 55, 909\u2013921 (2022).","journal-title":"Eur. J. Neurosci."},{"key":"67154_CR18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.isci.2020.101301","volume":"23","author":"F Shahbazi","year":"2020","unstructured":"Shahbazi, F., Grandi, V., Banerjee, A. & Trant, J. F. Cannabinoids and cannabinoid receptors: The story so far. iScience 23, 1013 (2020).","journal-title":"iScience"},{"key":"67154_CR19","first-page":"989","volume":"278","author":"VM Showalter","year":"1996","unstructured":"Showalter, V. M., Compton, D. R., Martin, B. R. & Abood, M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278, 989\u2013999 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"67154_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bmc.2004.09.050","volume":"13","author":"JW Huffman","year":"2005","unstructured":"Huffman, J. W. et al. Structure\u2013activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB1 and CB2 receptors: Steric and electronic effects of naphthoyl substituents. New highly selective CB2 receptor agonists. Bioorg. Med. Chem. 13, 89\u2013112 (2005).","journal-title":"Bioorg. Med. Chem."},{"key":"67154_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","volume":"97","author":"JL Wiley","year":"2014","unstructured":"Wiley, J. L., Marusich, J. A. & Huffman, J. W. Moving around the molecule: Relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 97, 55\u201363 (2014).","journal-title":"Life Sci."},{"key":"67154_CR22","first-page":"319","volume":"49","author":"MH Ullman-Culler\u00e9","year":"1999","unstructured":"Ullman-Culler\u00e9, M. H. & Foltz, C. J. Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab. Anim. Sci. 49, 319\u2013323 (1999).","journal-title":"Lab. Anim. Sci."},{"key":"67154_CR23","doi-asserted-by":"publisher","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids in Europe\u2014A review. www.emcdda.europa.eu (2021). https:\/\/doi.org\/10.2810\/4249.","DOI":"10.2810\/4249"},{"key":"67154_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","volume":"144","author":"MS Castaneto","year":"2014","unstructured":"Castaneto, M. S. et al. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 144, 12\u201341 (2014).","journal-title":"Drug Alcohol Depend."},{"key":"67154_CR25","doi-asserted-by":"publisher","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, 2018. Questions and answers for policymaking Medical use of cannabis and cannabinoids. (2018). https:\/\/doi.org\/10.2810\/979004","DOI":"10.2810\/979004"},{"key":"67154_CR26","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.3390\/ijms21176115","volume":"21","author":"KB Walsh","year":"2020","unstructured":"Walsh, K. B. & Andersen, H. K. Molecular pharmacology of synthetic cannabinoids: Delineating CB1 receptor-mediated cell signaling. Int. J. Mol. Sci. 21, 6115 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"67154_CR27","doi-asserted-by":"publisher","first-page":"10611","DOI":"10.1038\/s41598-021-90167-w","volume":"11","author":"A Zagzoog","year":"2021","unstructured":"Zagzoog, A. et al. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor. Sci. Rep. 11, 10611 (2021).","journal-title":"Sci. Rep."},{"key":"67154_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2826.2008.01671.x","volume":"20","author":"K Mackie","year":"2008","unstructured":"Mackie, K. Cannabinoid receptors: Where they are and what they do. J. Neuroendocrinol. 20, 10\u201314 (2008).","journal-title":"J. Neuroendocrinol."},{"key":"67154_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13041-021-00801-x","volume":"14","author":"H Miranzadeh Mahabadi","year":"2021","unstructured":"Miranzadeh Mahabadi, H., Bhatti, H., Laprairie, R. B. & Taghibiglou, C. Cannabinoid receptors distribution in mouse cortical plasma membrane compartments. Mol. Brain 14, 89 (2021).","journal-title":"Mol. Brain"},{"key":"67154_CR30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/bjsm.2004.011718","volume":"38","author":"A Dietrich","year":"2004","unstructured":"Dietrich, A. Endocannabinoids and exercise. Br. J. Sports Med. 38, 536\u2013541 (2004).","journal-title":"Br. J. Sports Med."},{"key":"67154_CR31","doi-asserted-by":"publisher","first-page":"17410","DOI":"10.1038\/s41598-017-17796-y","volume":"7","author":"Q-R Liu","year":"2017","unstructured":"Liu, Q.-R. et al. Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference. Sci. Rep. 7, 17410 (2017).","journal-title":"Sci. Rep."},{"key":"67154_CR32","doi-asserted-by":"publisher","first-page":"a009621","DOI":"10.1101\/cshperspect.a009621","volume":"2","author":"JL Lanciego","year":"2012","unstructured":"Lanciego, J. L., Luquin, N. & Obeso, J. A. Functional neuroanatomy of the basal ganglia. Cold Spring Harb. Perspect. Med. 2, a009621\u2013a009621 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"67154_CR33","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","volume":"11","author":"M Herkenham","year":"1991","unstructured":"Herkenham, M. et al. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J. Neurosci. 11, 563\u2013583 (1991).","journal-title":"J. Neurosci."},{"key":"67154_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S0091-3057(97)00422-X","volume":"59","author":"E Sulcova","year":"1998","unstructured":"Sulcova, E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59, 347\u2013352 (1998).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"67154_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1615\/CritRevNeurobiol.v13.i3.20","volume":"13","author":"F Chaperon","year":"1999","unstructured":"Chaperon, F. & Thiebot, M.-H. Behavioral effects of cannabinoid agents in animals. Crit. Rev. Neurobiol. 13, 243\u2013281 (1999).","journal-title":"Crit. Rev. Neurobiol."},{"key":"67154_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000057153","volume":"6","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl, K. R., Kolbe, H., Schneider, U. & Emrich, H. M. Cannabis in movement disorders. Complement. Med. Res. 6, 23\u201327 (1999).","journal-title":"Complement. Med. Res."},{"key":"67154_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1054\/plef.2001.0349","volume":"66","author":"V Di Marzo","year":"2002","unstructured":"Di Marzo, V., De Petrocellis, L., Fezza, F., Ligresti, A. & Bisogno, T. Anandamide receptors. Prostaglandins Leukot. Essent. Fat. Acids 66, 377\u2013391 (2002).","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"67154_CR38","doi-asserted-by":"publisher","first-page":"8870","DOI":"10.3390\/ijms21228870","volume":"21","author":"J Mlost","year":"2020","unstructured":"Mlost, J., Bryk, M. & Starowicz, K. Cannabidiol for pain treatment: Focus on pharmacology and mechanism of action. Int. J. Mol. Sci. 21, 8870 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"67154_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/toxics9100229","volume":"9","author":"I Klein","year":"2021","unstructured":"Klein, I. & Lehmann, H. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics 9, 229 (2021).","journal-title":"Toxics"},{"key":"67154_CR40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neuropharm.2013.08.016","volume":"76","author":"E Gornstein","year":"2014","unstructured":"Gornstein, E. & Schwarz, T. L. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 76, 175\u2013183 (2014).","journal-title":"Neuropharmacology"},{"key":"67154_CR41","first-page":"389","volume":"21","author":"G Cavaletti","year":"2000","unstructured":"Cavaletti, G. et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 21, 389\u2013393 (2000).","journal-title":"Neurotoxicology"},{"key":"67154_CR42","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1021\/acs.jmedchem.1c01912","volume":"65","author":"Y-F Chen","year":"2022","unstructured":"Chen, Y.-F. et al. Discovery of potential neuroprotective agents against paclitaxel-induced peripheral neuropathy. J. Med. Chem. 65, 4767\u20134782 (2022).","journal-title":"J. Med. Chem."},{"key":"67154_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175288","volume":"933","author":"Y Xu","year":"2022","unstructured":"Xu, Y., Jiang, Z. & Chen, X. Mechanisms underlying paclitaxel-induced neuropathic pain: Channels, inflammation and immune regulations. Eur. J. Pharmacol. 933, 175288 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"67154_CR44","doi-asserted-by":"publisher","first-page":"153473542110617","DOI":"10.1177\/15347354211061739","volume":"20","author":"S D\u2019Andre","year":"2021","unstructured":"D\u2019Andre, S. et al. Topical cannabinoids for treating chemotherapy-induced neuropathy: A case series. Integr. Cancer Ther. 20, 153473542110617 (2021).","journal-title":"Integr. Cancer Ther."},{"key":"67154_CR45","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/ph16071049","volume":"16","author":"S-I Filipiuc","year":"2023","unstructured":"Filipiuc, S.-I. et al. The skin and natural cannabinoids-topical and transdermal applications. Pharmaceuticals 16, 1049 (2023).","journal-title":"Pharmaceuticals"},{"key":"67154_CR46","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejim.2018.01.020","volume":"49","author":"MRD Brown","year":"2018","unstructured":"Brown, M. R. D. & Farquhar-Smith, W. P. Cannabinoids and cancer pain: A new hope or a false dawn?. Eur. J. Intern. Med. 49, 30\u201336 (2018).","journal-title":"Eur. J. Intern. Med."},{"key":"67154_CR47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/187152709789824660","volume":"8","author":"J Guindon","year":"2009","unstructured":"Guindon, J. & Hohmann, A. The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets 8, 403\u2013421 (2009).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"67154_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pain.2012.09.017","volume":"154","author":"MC Lee","year":"2013","unstructured":"Lee, M. C. et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain 154, 124\u2013134 (2013).","journal-title":"Pain"},{"key":"67154_CR49","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2174\/1381612820666141027115508","volume":"21","author":"J Zhang","year":"2014","unstructured":"Zhang, J. et al. Can modulating inflammatory response be a good strategy to treat neuropathic pain?. Curr. Pharm. Des. 21, 831\u2013839 (2014).","journal-title":"Curr. Pharm. Des."},{"key":"67154_CR50","doi-asserted-by":"publisher","unstructured":"Szabo, B. & Schlicker, E. Effects of Cannabinoids on Neurotransmission. In Cannabinoids 327\u2013365 (Springer). https:\/\/doi.org\/10.1007\/3-540-26573-2_11.","DOI":"10.1007\/3-540-26573-2_11"},{"key":"67154_CR51","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1523\/JNEUROSCI.4212-08.2009","volume":"29","author":"D Ryan","year":"2009","unstructured":"Ryan, D., Drysdale, A. J., Lafourcade, C., Pertwee, R. G. & Platt, B. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J. Neurosci. 29, 2053\u20132063 (2009).","journal-title":"J. Neurosci."},{"key":"67154_CR52","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0028-3908(00)00210-0","volume":"40","author":"VA Campbell","year":"2001","unstructured":"Campbell, V. A. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology 40, 702\u2013709 (2001).","journal-title":"Neuropharmacology"},{"key":"67154_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.neuropharm.2005.11.008","volume":"50","author":"AJ Drysdale","year":"2006","unstructured":"Drysdale, A. J., Ryan, D., Pertwee, R. G. & Platt, B. Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells. Neuropharmacology 50, 621\u2013631 (2006).","journal-title":"Neuropharmacology"},{"key":"67154_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1113\/jphysiol.2003.053900","volume":"555","author":"F Bergmann","year":"2004","unstructured":"Bergmann, F. & Keller, B. U. Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones from mouse. J. Physiol. 555, 45\u201359 (2004).","journal-title":"J. Physiol."},{"key":"67154_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106603","volume":"187","author":"RF Malheiro","year":"2023","unstructured":"Malheiro, R. F., Carmo, H., Carvalho, F. & Silva, J. P. Cannabinoid-mediated targeting of mitochondria on the modulation of mitochondrial function and dynamics. Pharmacol. Res. 187, 106603 (2023).","journal-title":"Pharmacol. Res."},{"key":"67154_CR56","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/01.anes.0000264765.33673.6c","volume":"106","author":"A Romero-Sandoval","year":"2007","unstructured":"Romero-Sandoval, A. & Eisenach, J. C. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 106, 787\u2013794 (2007).","journal-title":"Anesthesiology"},{"key":"67154_CR57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bjp.0707333","volume":"152","author":"EJ Rahn","year":"2007","unstructured":"Rahn, E. J., Makriyannis, A. & Hohmann, A. G. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br. J. Pharmacol. 152, 765\u2013777 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"67154_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejphar.2012.02.008","volume":"682","author":"E Burgos","year":"2012","unstructured":"Burgos, E. et al. Cannabinoid agonist WIN 55,212\u20132 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. Eur. J. Pharmacol. 682, 62\u201372 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"67154_CR59","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1124\/jpet.108.141994","volume":"327","author":"EJ Rahn","year":"2008","unstructured":"Rahn, E. J. et al. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J. Pharmacol. Exp. Ther. 327, 584\u2013591 (2008).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"67154_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/28393","volume":"394","author":"A Calignano","year":"1998","unstructured":"Calignano, A., Rana, G. L., Giuffrida, A. & Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 394, 277\u2013281 (1998).","journal-title":"Nature"},{"key":"67154_CR61","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.neuropharm.2005.12.002","volume":"50","author":"J Guindon","year":"2006","unstructured":"Guindon, J. & Beaulieu, P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50, 814\u2013823 (2006).","journal-title":"Neuropharmacology"},{"key":"67154_CR62","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/bjp.2008.322","volume":"155","author":"J Desroches","year":"2008","unstructured":"Desroches, J., Guindon, J., Lambert, C. & Beaulieu, P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br. J. Pharmacol. 155, 913\u2013924 (2008).","journal-title":"Br. J. Pharmacol."},{"key":"67154_CR63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40265-019-01132-x","volume":"79","author":"HL Blanton","year":"2019","unstructured":"Blanton, H. L. et al. Cannabinoids: Current and future options to treat chronic and chemotherapy-induced neuropathic pain. Drugs 79, 969\u2013995 (2019).","journal-title":"Drugs"},{"key":"67154_CR64","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1186\/s12885-018-4869-5","volume":"18","author":"Z Ghoreishi","year":"2018","unstructured":"Ghoreishi, Z. et al. Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer. BMC Cancer 18, 958 (2018).","journal-title":"BMC Cancer"},{"key":"67154_CR65","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/ACO.0000000000000775","volume":"32","author":"H Sharon","year":"2019","unstructured":"Sharon, H. & Brill, S. Cannabis-based medicines for chronic pain management. Curr. Opin. Anaesthesiol. 32, 623\u2013628 (2019).","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"67154_CR66","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert, N. et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLOS Biol. 18, e3000410 (2020).","journal-title":"PLOS Biol."},{"key":"67154_CR67","unstructured":"European Parliament, C. of the E. U. Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes Text with EEA relevance."},{"key":"67154_CR68","unstructured":"Leary, S. L. & American Veterinary Medical Association. AVMA guidelines for the euthanasia of animals: 2020 edition."},{"key":"67154_CR69","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/biom11050766","volume":"11","author":"C Griffiths","year":"2021","unstructured":"Griffiths, C., Aikins, J., Warshal, D. & Ostrovsky, O. Can cannabidiol affect the efficacy of chemotherapy and epigenetic treatments in cancer?. Biomolecules 11, 766 (2021).","journal-title":"Biomolecules"},{"key":"67154_CR70","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3389\/fphar.2018.00889","volume":"9","author":"US Kosgodage","year":"2018","unstructured":"Kosgodage, U. S. et al. Cannabidiol (CBD) is a novel inhibitor for exosome and microvesicle (EMV) release in cancer. Front. Pharmacol. 9, 889 (2018).","journal-title":"Front. Pharmacol."},{"key":"67154_CR71","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1212\/WNL.44.3_Part_1.488","volume":"44","author":"AJ Windebank","year":"1994","unstructured":"Windebank, A. J., Smith, A. G. & Russell, J. W. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 44, 488\u2013488 (1994).","journal-title":"Neurology"},{"key":"67154_CR72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1365-2990.2012.01295.x","volume":"39","author":"G \u00d6zt\u00fcrk","year":"2013","unstructured":"\u00d6zt\u00fcrk, G. et al. Two distinct types of dying back axonal degeneration in vitro. Neuropathol. Appl. Neurobiol. 39, 362\u2013376 (2013).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"67154_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfw254","author":"L Guo","year":"2017","unstructured":"Guo, L. et al. Multiparametric image analysis of rat dorsal root ganglion cultures to evaluate peripheral neuropathy-inducing chemotherapeutics. Toxicol. Sci. https:\/\/doi.org\/10.1093\/toxsci\/kfw254 (2017).","journal-title":"Toxicol. Sci."},{"key":"67154_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114520","volume":"188","author":"SH Park","year":"2021","unstructured":"Park, S. H. et al. Usefulness of the measurement of neurite outgrowth of primary sensory neurons to study cancer-related painful complications. Biochem. Pharmacol. 188, 114520 (2021).","journal-title":"Biochem. Pharmacol."},{"key":"67154_CR75","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/brain\/awab113","volume":"144","author":"EJ Akin","year":"2021","unstructured":"Akin, E. J. et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 144, 1727\u20131737 (2021).","journal-title":"Brain"},{"key":"67154_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1742-2094-9-49","volume":"9","author":"C Scuderi","year":"2012","unstructured":"Scuderi, C. et al. Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-\u03b1. J. Neuroinflammation 9, 49 (2012).","journal-title":"J. Neuroinflammation"},{"key":"67154_CR77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/jcm9020428","volume":"9","author":"S Beggiato","year":"2020","unstructured":"Beggiato, S., Tomasini, M. C., Cassano, T. & Ferraro, L. Chronic oral palmitoylethanolamide administration rescues cognitive deficit and reduces neuroinflammation, oxidative stress, and glutamate levels in a transgenic murine model of Alzheimer\u2019s disease. J. Clin. Med. 9, 428 (2020).","journal-title":"J. Clin. Med."},{"key":"67154_CR78","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/biom12121873","volume":"12","author":"A Elfarnawany","year":"2022","unstructured":"Elfarnawany, A. & Dehghani, F. Palmitoylethanolamide mitigates paclitaxel toxicity in primary dorsal root ganglion neurons. Biomolecules 12, 1873 (2022).","journal-title":"Biomolecules"},{"key":"67154_CR79","doi-asserted-by":"publisher","DOI":"10.1787\/9789264071001-en","volume-title":"Test No. 423: Acute Oral Toxicity\u2014Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4","author":"OECD","year":"2002","unstructured":"OECD. Test No. 423: Acute Oral Toxicity\u2014Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4 (OECD, 2002). https:\/\/doi.org\/10.1787\/9789264071001-en."},{"key":"67154_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/0471141755.ph1010s27","volume":"27","author":"S Roux","year":"2004","unstructured":"Roux, S., Sabl\u00e9, E. & Porsolt, R. D. Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effects on behavior and physiological function. Curr. Protoc. Pharmacol. 27, 1\u201323 (2004).","journal-title":"Curr. Protoc. Pharmacol."},{"key":"67154_CR81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/ph16050694","volume":"16","author":"L-E Filipiuc","year":"2023","unstructured":"Filipiuc, L.-E. et al. Acute toxicity and pharmacokinetic profile of an EU-GMP-certified Cannabis sativa L. in Rodents. Pharmaceuticals 16, 694 (2023).","journal-title":"Pharmaceuticals"},{"key":"67154_CR82","unstructured":"NC3Rs. Blood sampling: Mouse. https:\/\/www.nc3rs.org.uk\/3rs-resources\/blood-sampling\/blood-sampling-mouse."},{"key":"67154_CR83","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0304-3959(01)00363-3","volume":"94","author":"RC Polomano","year":"2001","unstructured":"Polomano, R. C. et al. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 94, 293\u2013304 (2001).","journal-title":"Pain"},{"key":"67154_CR84","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neulet.2005.12.013","volume":"397","author":"SJL Flatters","year":"2006","unstructured":"Flatters, S. J. L., Xiao, W.-H. & Bennett, G. J. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett. 397, 219\u2013223 (2006).","journal-title":"Neurosci. Lett."},{"key":"67154_CR85","first-page":"507","volume":"58","author":"CE Zb\u00e2rcea","year":"2017","unstructured":"Zb\u00e2rcea, C. E. et al. Therapeutic potential of certain drug combinations on paclitaxel-induced peripheral neuropathy in rats. Rom. J. Morphol. Embryol. 58, 507\u2013516 (2017).","journal-title":"Rom. J. Morphol. Embryol."},{"key":"67154_CR86","first-page":"414","volume":"59","author":"CE Zb\u00e2rcea","year":"2011","unstructured":"Zb\u00e2rcea, C. E., Negre\u015f, S. & Chiri\u0163\u01ce, C. Gabapentin, alone and associated with tramadol reduces peripheral paclitaxel-induced neuropathy in rats. Farmacia 59, 414\u2013423 (2011).","journal-title":"Farmacia"},{"key":"67154_CR87","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.3390\/ijms23179564","volume":"23","author":"PP Lakatos","year":"2022","unstructured":"Lakatos, P. P. et al. The acute antiallodynic effect of tolperisone in rat neuropathic pain and evaluation of its mechanism of action. Int. J. Mol. Sci. 23, 9564 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"67154_CR88","first-page":"597","volume":"53","author":"D Le Bars","year":"2001","unstructured":"Le Bars, D., Gozariu, M. & Cadden, S. W. Animal models of nociception. Pharmacol. Rev. 53, 597\u2013652 (2001).","journal-title":"Pharmacol. Rev."},{"key":"67154_CR89","volume-title":"Animal Experiments in Pharmacological Analysis","author":"F Domer","year":"1971","unstructured":"Domer, F. Animal Experiments in Pharmacological Analysis Vol. XII (Charles C. Thomas, 1971)."},{"key":"67154_CR90","doi-asserted-by":"publisher","unstructured":"Screening Methods in Pharmacology (Elsevier, 1971). https:\/\/doi.org\/10.1016\/C2013-0-11630-3","DOI":"10.1016\/C2013-0-11630-3"},{"key":"67154_CR91","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0750-7658(01)00399-9","volume":"20","author":"D Le Bars","year":"2001","unstructured":"Le Bars, D., Gozariu, M. & Cadden, S. II. Analyse critique des mod\u00e8les animaux de douleur aigu\u00eb. Seconde partie. Ann. Fr. Anesth. Reanim. 20, 452\u2013470 (2001).","journal-title":"Ann. Fr. Anesth. Reanim."},{"key":"67154_CR92","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1046\/j.1526-4637.2001.002001008.x","volume":"2","author":"RC Polomano","year":"2001","unstructured":"Polomano, R. C. & Bennett, G. J. Chemotherapy-evoked Painful Peripheral Neuropathy. Pain Med. 2, 8\u201314 (2001).","journal-title":"Pain Med."},{"key":"67154_CR93","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3389\/fnmol.2017.00284","volume":"10","author":"JR Deuis","year":"2017","unstructured":"Deuis, J. R., Dvorakova, L. S. & Vetter, I. Methods used to evaluate pain behaviors in rodents. Front. Mol. Neurosci. 10, 284 (2017).","journal-title":"Front. Mol. Neurosci."},{"key":"67154_CR94","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1474-4422(14)70102-4","volume":"13","author":"TS Jensen","year":"2014","unstructured":"Jensen, T. S. & Finnerup, N. B. Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms. Lancet Neurol. 13, 924\u2013935 (2014).","journal-title":"Lancet Neurol."},{"key":"67154_CR95","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1089\/neu.2010.1700","volume":"29","author":"E Santos-Nogueira","year":"2012","unstructured":"Santos-Nogueira, E., Redondo Castro, E., Mancuso, R. & Navarro, X. Randall-Selitto test: A new approach for the detection of neuropathic pain after spinal cord injury. J. Neurotrauma 29, 898\u2013904 (2012).","journal-title":"J. Neurotrauma"},{"key":"67154_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245813","volume":"16","author":"MS Minett","year":"2021","unstructured":"Minett, M. S., Eijkelkamp, N. & Wood, J. N. Correction: Significant determinants of mouse pain behaviour. PLoS ONE 16, e0245813 (2021).","journal-title":"PLoS ONE"},{"key":"67154_CR97","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/bcp.13281","volume":"83","author":"S Dimmitt","year":"2017","unstructured":"Dimmitt, S., Stampfer, H. & Martin, J. H. When less is more\u2014efficacy with less toxicity at the ED50. Br. J. Clin. Pharmacol. 83, 1365\u20131368 (2017).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"67154_CR98","first-page":"184","volume":"21","author":"MA Randhawa","year":"2009","unstructured":"Randhawa, M. A. Calculation of LD50 values from the method of Miller and Tainter, 1944. J. Ayub Med. Coll. Abbottabad 21, 184\u2013185 (2009).","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"67154_CR99","doi-asserted-by":"publisher","DOI":"10.1787\/9789264070684-en","volume-title":"Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents","author":"OECD","year":"2008","unstructured":"OECD. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents (OECD, 2008). https:\/\/doi.org\/10.1787\/9789264070684-en."},{"key":"67154_CR100","doi-asserted-by":"publisher","first-page":"121","DOI":"10.22543\/7674.61.P121129","volume":"2019","author":"C Chiri\u021b\u0103","year":"2019","unstructured":"Chiri\u021b\u0103, C. et al. Experimental pharmacological research regarding some new quinazolin-4-ones derivatives. J. Mind Med. Sci. 2019, 121\u2013129. https:\/\/doi.org\/10.22543\/7674.61.P121129 (2019).","journal-title":"J. Mind Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67154-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67154-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T03:09:01Z","timestamp":1721012941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67154-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67154"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67154-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16242"}}